1887

Chapter 112 : Histocompatibility and Immunogenetics Testing in the 21st Century

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Histocompatibility and Immunogenetics Testing in the 21st Century, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH112-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH112-2.gif

Abstract:

The scope of immunogenetics and histocompatibility testing in transplantation has changed dramatically over the past 50 years. In organ transplantation, outcomes continue to improve as a result of better immunogenetics testing, immune suppression, and patient management; however, acute rejection and chronic rejection remain the biggest obstacles for successful transplantation. Since “crossmatching” was first described by Patel and Terasaki (1), the goal to provide accurate immunological risk assessment for transplant recipients remains unchanged. Histocompatibility and immunogenetics laboratories utilize multiple diagnostic assays to evaluate HLA compatibility between donors and recipients. Furthermore, testing has expanded to include immunogenetics systems other than those using HLA, such as killer immunoglobulin-like receptors (KIR) (2, 3), major histocompatibility complex (MHC) class I chain-related gene A (MICA) (4), angiotensin type 1 receptor (AT1R) (5), and genes encoding cytokines. The application of new state-of-the-art diagnostic tests that inform on the immune status of the transplant recipient has transformed the role of the immunogenetics laboratory from providing tissue-typing and crossmatching services to assessing immunologic risk, donor selection, and presentation of strategies for desensitization and therapeutic intervention. In addition, immunological risk assessment is no longer limited to the pretransplant period but has become increasingly recognized as a noninvasive tool for assessing acute and chronic rejection (6–8).

Citation: Zhang Q, Reed E. 2016. Histocompatibility and Immunogenetics Testing in the 21st Century, p 1063-1068. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch112
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555818722.ch112
1. Patel R, Terasaki PI. 1969. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280:735739.[CrossRef].[PubMed]
2. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS. 2010. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116:24112419.[CrossRef].[PubMed]
3. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC. 2012. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 367:805816.[CrossRef].[PubMed]
4. Terasaki PI, Ozawa M, Castro R. 2007. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 7:408415.[CrossRef].[PubMed]
5. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schönemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G. 2005. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352:558569.[CrossRef].[PubMed]
6. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S. 2009. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 87:16811688.[CrossRef].[PubMed]
7. Hoshino J, Kaneku H, Everly MJ, Greenland S, Terasaki PI. 2012. Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation 93:11731178.[CrossRef].[PubMed]
8. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, Goldberg A, Birk PE, Rush DN, Nickerson PW. 2012. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 12:11571167.[CrossRef].[PubMed]
9. Shiina T, Suzuki S, Ozaki Y, Taira H, Kikkawa E, Shigenari A, Oka A, Umemura T, Joshita S, Takahashi O, Hayashi Y, Paumen M, Katsuyama Y, Mitsunaga S, Ota M, Kulski JK, Inoko H. 2012. Super high resolution for single molecule-sequence-based typing of classical HLA loci at the 8-digit level using next generation sequencers. Tissue Antigens 80:305316.[CrossRef].[PubMed]
10. Ozaki Y, Suzuki S, Shigenari A, Okudaira Y, Kikkawa E, Oka A, Ota M, Mitsunaga S, Kulski JK, Inoko H, Shiina T. 2014. HLA-DRB1, -DRB3, -DRB4 and -DRB5 genotyping at a super-high resolution level by long range PCR and high-throughput sequencing. Tissue Antigens 83:1016.[CrossRef].[PubMed]
11. Terasaki P, Mickey MR, Singal DP, Mittal KK, Patel R. 1968. Serotyping for homotransplantation. XX. Selection of recipients for cadaver donor transplants. N Engl J Med 279:11011103.[CrossRef].[PubMed]
12. Cecka JM. 2010. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant 10:2629.[CrossRef].[PubMed]
13. Montgomery RA, Gentry SE, Marks WH, Warren DS, Hiller J, Houp J, Zachary AA, Melancon JK, Maley WR, Rabb H, Simpkins C, Segev DL. 2006. Domino paired kidney donation: a strategy to make best use of live non-directed donation. Lancet 368:419421.[CrossRef].[PubMed]
14. Rees MA, Kopke JE, Pelletier RP, Segev DL, Rutter ME, Fabrega AJ, Rogers J, Pankewycz OG, Hiller J, Roth AE, Sandholm T, Unver MU, Montgomery RA. 2009. A nonsimultaneous, extended, altruistic-donor chain. N Engl J Med 360:10961101.[CrossRef].[PubMed]
15. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL. 2011. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 365:318326.[CrossRef].[PubMed]
16. Morrow WR, Frazier EA, Mahle WT, Harville TO, Pye SE, Knecht KR, Howard EL, Smith RN, Saylors RL, Garcia X, Jaquiss RD, Woodle ES. 2012. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 93:319324.[CrossRef].[PubMed]
17. Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Naim M, Wang Q, Jordan SC. 2008. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 86:820825.[CrossRef].[PubMed]
18. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM. 2011. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11:24052413.[CrossRef].[PubMed]
19. Opelz G Collaborative Transplant Study. 2005. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 365:15701576.[CrossRef].[PubMed]
20. Zhang Q, Reed EF. 2010. Non-MHC antigenic targets of the humoral immune response in transplantation. Curr Opin Immunol 22:682688.[CrossRef].[PubMed]
21. Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Cendales L, Demetris AJ, Drachenberg CB, Farver CF, Rodriguez ER, Wallace WD, Glotz D Banff Meeting Report Writing Committee. 2012. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 12:563570.[CrossRef].[PubMed]
22. Sacks SH, Zhou W. 2012. The role of complement in the early immune response to transplantation. Nat Rev Immunol 12:431442.[CrossRef].[PubMed]
23. Bartel G, Brown K, Phillips R, Peng Q, Zhou W, Sacks SH, Wong W. 2013. Donor specific transplant tolerance is dependent on complement receptors. Transplant Int 26:99108.[CrossRef]
24. Fürst D, Müller C, Vucinic V, Bunjes D, Herr W, Gramatzki M, Schwerdtfeger R, Arnold R, Einsele H, Wulf G, Pfreundschuh M, Glass B, Schrezenmeier H, Schwarz K, Mytilineos J. 2013. High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. Blood 122:32203229.[CrossRef].[PubMed]
25. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, Anasetti C. 2007. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110:45764583.[CrossRef].[PubMed]
26. Loiseau P, Busson M, Balere ML, Dormoy A, Bignon JD, Gagne K, Gebuhrer L, Dubois V, Jollet I, Bois M, Perrier P, Masson D, Moine A, Absi L, Reviron D, Lepage V, Tamouza R, Toubert A, Marry E, Chir Z, Jouet JP, Blaise D, Charron D, Raffoux C. 2007. HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant 13:965974.[CrossRef].[PubMed]
27. Fleischhauer K, Shaw BE, Gooley T, Malkki M, Bardy P, Bignon JD, Dubois V, Horowitz MM, Madrigal JA, Morishima Y, Oudshoorn M, Ringden O, Spellman S, Velardi A, Zino E, Petersdorf EW International Histocompatibility Working Group in Hematopoietic Cell Transplantation. 2012. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol 13:366374.[CrossRef].[PubMed]
28. Delaney C, Bollard CM, Shpall EJ. 2013. Cord blood graft engineering. Biol Blood Marrow Transplant 19(Suppl 1):S74S78.[CrossRef].[PubMed]
29. Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, Loberiza FR, Champlin RE, Klein JP, Horowitz MM, Wagner JE. 2007. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 369:19471954.[CrossRef].[PubMed]
30. Khan F, Agarwal A, Agrawal S. 2004. Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme. Bone Marrow Transplant 34:112.[CrossRef].[PubMed]
31. Lion T. 2007. Detection of impending graft rejection and relapse by lineage-specific chimerism analysis. Methods Mol Med 134:197216.[PubMed].[CrossRef]

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error